Thomas Charles Reilly - Mar 3, 2022 Form 4 Insider Report for Cara Therapeutics, Inc. (CARA)

Role
Chief Financial Officer
Signature
/s/ Darren DeStefano, Attorney-in-Fact
Stock symbol
CARA
Transactions as of
Mar 3, 2022
Transactions value $
-$23,261
Form type
4
Date filed
3/4/2022, 04:54 PM
Previous filing
Mar 1, 2022
Next filing
Jul 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CARA Common Stock Sale -$23.3K -2.04K -5.13% $11.38 37.8K Mar 3, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on June 14, 2021 to satisfy the tax withholding obligations triggered by the vesting of performance-based RSUs reported in the Form 4 filed with the Securities and Exchange Commission on March 1, 2022, and does not represent a discretionary trade by the Reporting Person.